Living Longer is Possible—and Proven

Overall Survival Results

KISQALI is proven to help women live longer

KISQALI® (ribociclib) is the first and only medication in its class that's proven in multiple clinical trials to help women live longer with HR+, HER2- metastatic breast cancer (mBC). Now, women with mBC—confident, informed, and determined—are learning what it means to live longer. They call themselves the Thrivers, and you're about to see why


Results for premenopausal women taking KISQALI + a nonsteroidal aromatase inhibitor (NSAI) + goserelin

KISQALI was studied in a clinical trial dedicated exclusively to younger women. The median age was 44 years (range 25 to 58). 495 women were treated with KISQALI + an NSAI (i.e. letrozole or anastrozole) + goserelin or an NSAI + goserelin.

Results for postmenopausal women taking KISQALI + fulvestrant

In a clinical trial with 726 women, 484 were treated with KISQALI + fulvestrant and 242 women were treated with fulvestrant alone.